BASF and Eight Partners Cooperate to Optimize Production Processes for Renewable-Based Products
A consortium of companies in the European process industry from the areas of biotechnology, renewable resources, chemistry, process engineering, equipment supply, as well as research organizations recently launched project PRODIAS (PROcessing Diluted Aqueous Systems). The project focuses on unlocking the potential of renewable-based products made via white biotechnology, by significantly decreasing production costs, increasing productivity and efficiency, lowering energy consumption, and accelerating process developments.
Under the consortial leadership of BASF, the partners include Cargill Haubourdin, France; University of Kaiserslautern, Germany; Imperial College London, UK; Alfa Laval, Sweden; GEA Messo PT, the Netherlands; Xendo, the Netherlands; UPM, Finland; and Enviplan, Germany. These partners will collaborate to develop cost and energy-efficient technologies for water purification, removal and product-recovery needed to support downstream processing in white biotechnology.
Using biotechnological methods such as fermentation or biocatalysis, in most cases the renewable-based products are produced as part of complex dilute aqueous mixtures from which they have to be purified. This includes the removal of a vast amount of water, making the downstream process energy intensive as it often requires many complex consecutive separation steps and thus hampers the cost-competitiveness of products from renewable resources. Furthermore, processing methods developed for chemical production are often used which are insufficiently adapted to biotechnological processes.
PRODIAS aims to address these challenges by developing and implementing cost-effective separation and purification technologies tailored for renewable resources in white biotechnology production processes. Its focus is to adapt separation techniques to the need of white biotechnology products and to design novel hybrid systems combining individual advantages, for example, selectivity and energy efficiency. The bioreactions (fermentations) and biocatalysis by which the valuable products are produced are subject to alteration and optimization, to enable more efficient and resource-saving downstream processing.
The total project budget is about €14 million with the European Union contributing €10 million. EU funding of the PRODIAS project is enabled via the Public-Private Partnership with SPIRE (Sustainable Process Industry through Resource and Energy Efficiency). SPIRE, in turn, is part of Horizon 2020, the EU framework program for research and innovation, which runs from 2014 to 2020 and comprises an €80 billion budget. In partnership with industry, the EU will invest in innovative technologies for sustainable processes.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance